BioPharmSignal logoBioPharmSignal

Biotech News

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Capricor Therapeutics (CAPR)Capricor TherapeuticsFDA / regulatory

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CAPRCapricor Therapeutics2026-08-24 13:25 EST

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

ARWRArrowhead Pharmaceuticals2026-10-07 11:30 EST

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

PHARPharming Group2026-09-25 14:30 EST

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

RHHBYRoche Holdings AG2026-09-18 10:45 EST

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

RAREUltragenyx Pharmaceutical2026-09-17 19:48 EST

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

View all latest news

Capricor Therapeutics

Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The...

Recent company news

CAPRCapricor Therapeutics2026-10-05 13:00 EST

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

CAPRCapricor Therapeutics2026-09-17 12:30 EST

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

CAPRCapricor Therapeutics2026-08-24 13:25 EST

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-08-10 12:30 EST

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

Stock data

Close
7.75 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States